NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

血癌治療藥的全球市場(2020年∼2027年)

Global Blood Cancer Drugs Market - 2020-2027

出版商 DataM Intelligence 商品編碼 1008252
出版日期 內容資訊 英文 180 Pages
商品交期: 約2個工作天內
價格
血癌治療藥的全球市場(2020年∼2027年) Global Blood Cancer Drugs Market - 2020-2027
出版日期: 2021年05月27日內容資訊: 英文 180 Pages
簡介

血癌治療藥市場成長,醫療保健專業人員和患者對癌症早期診斷潛力的認識提高,政府對研究的資助增加將加速市場增長。還有法規當局制定新的血癌藥物開發新監管認證更可望促進市場增長。然而,高昂的藥物審批成本阻礙了血癌藥物市場的增長。

本報告提供全球血癌治療藥市場的相關調查,提供市場機會和影響,成長及阻礙因素,類型·藥物類型·給藥途徑·終端用戶·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 全球血癌治療藥市場調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 全球血癌治療藥市場-市場定義和概要

第3章 全球血癌治療藥市場-摘要整理

  • 各類型的市場明細
  • 各藥物類型的市場明細
  • 各給藥途徑的市場明細
  • 各終端用戶市場明細
  • 各地區的市場明細

第4章 全球血癌治療藥市場-市場動態

  • 影響市場的要素
    • 成長要素
    • 阻礙因素
    • 高藥物審批成本阻礙血癌藥物市場增長
    • 市場機會
    • 影響分析

第5章 全球血癌治療藥市場-產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 全球血癌治療藥市場-COVID-19分析

  • 市場上的Covid-19分析
    • COVID-19前的市場方案
    • 當前的 COVID-19 市場情景
    • COVID-19後的市場方案或未來情景
  • Covid-19的價格趨勢
  • 需求與供給的頻譜
  • 疫情期間與市場相關的政府舉措
  • 製造商策略性舉措
  • 結論

第7章 全球血癌治療藥市場-各類型

  • 簡介
  • 市場規模分析及與前一年同期比較成長分析
  • 市場魅力指數
    • 白血病
    • 非何杰金氏淋巴瘤
    • 何杰金氏淋巴瘤
    • 骨髓瘤

第8章 全球血癌治療藥市場-醫各類型藥品

  • 簡介
  • 市場規模分析及與前一年同期比較成長分析
  • 市場魅力指數
    • ritsuakisan/mabutera(Rituximab)
    • Gleevec/Glivec(Imatinib)
    • Revlimid(Lenalidomide)
    • 貝爾Keido(Bortezomib)
    • Tasigna(Nilotinib)
    • Pomalyst(Pomalidomide)
    • bidaza(Azacitidine)
    • kipurorisu(Carfilzomib)
    • Adcetris(Brentuximab Vedotin)
    • 其他

第9章 全球血癌治療藥市場-各給藥途徑

  • 簡介
  • 市場規模分析及與前一年同期比較成長分析
  • 市場魅力指數
    • 口服
    • 非口服
    • 其他

第10章 全球血癌治療藥市場-各終端用戶

  • 簡介
  • 市場規模分析及與前一年同期比較成長分析
  • 市場魅力指數
    • 醫院
    • 診所
    • 門診病人手術中心

第11章 全球血癌治療藥市場-各地區

  • 簡介
  • 市場規模分析及與前一年同期比較成長分析
  • 市場魅力指數
  • 北美
    • 簡介
    • 主要每個地區的動態
    • 各類型:市場規模分析,及與前一年同期比較成長分析
    • 各藥物類型:市場規模分析,及與前一年同期比較成長分析
    • 各給藥途徑:市場規模分析,及與前一年同期比較成長分析
    • 各終端用戶:市場規模分析,及與前一年同期比較成長分析
    • 各國:市場規模分析,及與前一年同期比較成長分析
  • 歐洲
    • 簡介
    • 主要每個地區的動態
    • 各類型:市場規模分析,及與前一年同期比較成長分析
    • 各藥物類型:市場規模分析,及與前一年同期比較成長分析
    • 各給藥途徑:市場規模分析,及與前一年同期比較成長分析
    • 各終端用戶:市場規模分析,及與前一年同期比較成長分析
    • 各國:市場規模分析,及與前一年同期比較成長分析
  • 南美
    • 簡介
    • 主要每個地區的動態
    • 各類型:市場規模分析,及與前一年同期比較成長分析
    • 各藥物類型:市場規模分析,及與前一年同期比較成長分析
    • 各給藥途徑:市場規模分析,及與前一年同期比較成長分析
    • 各終端用戶:市場規模分析,及與前一年同期比較成長分析
    • 各國:市場規模分析,及與前一年同期比較成長分析
  • 亞太地區
    • 簡介
    • 主要每個地區的動態
    • 各類型:市場規模分析,及與前一年同期比較成長分析
    • 各藥物類型:市場規模分析,及與前一年同期比較成長分析
    • 各給藥途徑:市場規模分析,及與前一年同期比較成長分析
    • 各終端用戶:市場規模分析,及與前一年同期比較成長分析
    • 各國:市場規模分析,及與前一年同期比較成長分析
  • 中東和非洲
    • 簡介
    • 主要每個地區的動態
    • 各類型:市場規模分析,及與前一年同期比較成長分析
    • 各藥物類型:市場規模分析,及與前一年同期比較成長分析
    • 各給藥途徑:市場規模分析,及與前一年同期比較成長分析
    • 各終端用戶:市場規模分析,及與前一年同期比較成長分析

第12章 全球血癌治療藥市場-競爭情形

  • 競爭模式
  • 市場地位/佔有率分析
  • 合併和收購分析

第13章 全球血癌治療藥市場-企業簡介概要

  • Amgen Inc.
    • 企業概要
    • 產品系列·概要
    • 要點
    • 財務概要
  • AstraZeneca PLC
  • Bayer AG
  • Celgene Corporation
  • Eli Lilly
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Takeda Pharmaceutical Company Limited
  • Daiichi Sankyo Company, Limited
  • UCB SA

第14章 全球血癌治療藥市場-重要考察

第15章 全球血癌治療藥市場-DataM

  • 附錄
  • 關於本公司·服務
  • 諮詢方式

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Market Overview

The global blood cancer drugs market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Blood cancer is a serious and life-threatening cancer that affects either production or function of blood cells such as bone marrow and tissues which results in dysfunctional of lymphatic system. The characteristics sign and symptoms of blood cancer is severe abdominal pain, bone and joints pain, gradually weight loss, dark spots, excessive or easy bruising and weakness. Blood cancers occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells.

Globally, blood cancer are the fifth most common cancer and is the second most leading cause of cancer deaths. The global blood cancer drugs market is projected to register a moderate growth rate in the market and which is anticipated due to, high demand of diseases specific treatment, rise in adoption of newer technologies, presence of refined healthcare infrastructure and increased patient awareness level as well as high prevalence of blood cancer.

Market Dynamics

The blood cancer drugs market growth is driven by increase awareness amongst healthcare professionals and patients about the possibility of early diagnosis of cancer, increase in government funding for research is anticipated to accelerate the market growth during the forecast period. Institutes like National Cancer Institute (NCI) receive funds from U.S. congress to support cancer-related activities, are expected to drive the market growth in the forecast period.

The growing death incidences and increasing prevalence of blood cancer cases across the globe

The blood cancer drugs market is being driven by the growing death incidences and increasing prevalence of blood cancer cases across the globe. Different types of blood cancers such as lymphoma, leukaemia, myeloma and others have different risk factors where some can be controlled or prevented through drug therapies and others may lead to death.

According to Bristol-Myers Squibb Company report, over 1.85 million new blood cancer cases are expected to be diagnosed across the globe in 2040, out of which 918,872 cases are from lymphoma, 656,345 from leukaemia, and 275,047 cases myeloma.

Furthermore, the report estimated, in 2040, the approximate number of deaths worldwide due to blood cancer will be 1,100,000. In 2019, more than 387,000 people are living with leukaemia in the United States and an estimated 68,000 deaths will result from blood cancer.

According to national cancer institute, the estimated deaths due to blood cancer are expected to be around 22,840 in 2019. The increasing deaths and increasing incidence of blood cancer cases globally drives the blood cancer drugs market.

Formulations of new regulatory approvals for new drugs for blood cancer are expected to boost the growth

The formulations of new regulatory approvals for new drugs for blood cancer are expected to boost the growth of market. For instance, in 2015, Pfizer announced that inotuzumab (antibody-drug conjugate) received a breakthrough therapy designation from U.S. FDA for acute lymphoblastic leukemia.

Increasing awareness amongst healthcare professionals and patients about the possibility of early diagnosis of cancer and increase in government funding for research is anticipated to accelerate the market growth during the forecast period. Institutes like National Cancer Institute (NCI) receive funds from U.S. congress to support cancer-related activities.

High drug approval costs hinders the growth of the blood cancer drugs market

However, Drug approval involves series of research stages and regulatory approvals that are often expensive. Drug approval process include about four phases of clinical trials and various stages of screening process with the regulatory body such as FDA. The costs of failed clinical trials are also high as clinical trial phases involves huge investments. According to Tufts Centre for the Study of Drug Development, the cost of bringing a new drug from its conception to shelves is about $2.7 billion. Thus indicating that the high drug approval costs hinders the growth of the blood cancer drugs market.

COVID-19 Impact Analysis

Due to the outbreak of the COVID-19, the market observed a significant setback in terms of growth. As the COVID-19 cases were rising, the healthcare system had shifted its focus in curbing the disease thereby resulting in the delay of diagnosis and treatment of other chronic conditions like blood cancer.

Thus, a negative impact is expected on the blood cancer drugs market due to the pandemic scenario. However, in the coming years, a significant rise is expected in the diagnostic procedures related to cancer.

Segment Analysis

By type , the blood cancer drugs market is classified into leukemia, non-hodgkin lymphoma, hodgkin lymphoma, and myeloma.

Leukemia segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)

Leukemia is a blood cancer that originates in the blood and bone marrow. It occurs when the body creates too many abnormal white blood cells and interferes with the bone marrow's ability to make red blood cells and platelets.

It causes the body to make white blood cells that grow out of control and live longer than they're supposed to. And unlike normal white blood cells, they don't help body fight infection. Over time, the leukemia cells crowd out or suppress the development of normal cells. The rate at which leukemia progresses and how the cells replace the normal blood and marrow cells are different with each type of leukemia. After diagnosis and treatment, many people with leukemia live many good, quality years. The presence of best-selling brands like Rituxan, Imbruvica, and Glivec, which are reported to be some of the highest revenue-generating leukemia drugs are driving the market growth.

Non-Hodgkin lymphoma has the second largest share in the segment. Non-Hodgkin lymphoma (also known as non-Hodgkin's lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in white blood cells called lymphocytes, which are part of the body's immune system.

Advances in diagnosis and treatment of non-Hodgkin's lymphoma have helped improve the prognosis for people with this disease. In most cases, people diagnosed with non-Hodgkin's lymphoma don't have any obvious risk factors. And many people who have risk factors for the disease never develop it.

On the basis of drugs type, the the blood cancer drugs market is classified into Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Others.

The Rituaxan/Mabthera (Rituximab) drugs segment are expected to dominate the blood cancer drugs market during the forecast period

The Mabthera was the first therapeutic monoclonal antibody to target cells that have the CD20 marker on their surface. These cells are central to many blood cancers, including common forms of lymphoma and leukaemia. Mabthera attacks these cells both directly and together with the body's immune system.

In the United States, Europe and in other countries, Mabthera is approved for the treatment of adults with the following blood cancers, previously untreated and relapsed/refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma, and previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Mabthera is also approved for the treatment of adults in auto-immune diseases, severe active rheumatoid arthritis, pemphigus vulgaris and severe active granulomatosis with polyangiitis and microscopic polyangiitis (GPA/MPA).

Gleevac/Glivec (Imatinib) has also second largest share in the market. NCI-supported research led to a series of discoveries that resulted in the development of imatinib (Gleevec), a landmark drug that has vastly improved the outcomes of patients with a type of blood cancer called chronic myelogenous leukemia. These discoveries also helped establish a new group of drugs (known as targeted therapy) that has changed the field of cancer research.

Geographical Analysis

North America region holds the largest market share global blood cancer drugs market

North America region is dominating the global blood cancer drugs market accounted for the largest market share in 2019, owing to the presence of key players in the region, availability of sophisticated healthcare infrastructure, and increasing awareness of blood cancer. Besides, favorable government initiatives and increase in number of research collaborations are some of the drivers expected to accelerate the market growth. In 2019, Eli Lilly, a US-based Pharmaceutical company, acquired Loxo Oncology, a cancer-focused biotechnology company for $8 billion. This acquisition of Loxo Oncology provides Lilly with a promising pipeline of investigational medicines such as oral RET inhibitor, oral BTK inhibitor and others. The deal would enable Lilly to attain strong patent on Loxo's genetically based approach to treat cancer. Loxo Oncology, is a biopharmaceutical company, developing and selling medicines for patients with genetically defined cancers.

On the other hand, Asia-Pacific is expected to exhibit the fastest growth rate over the forecast period owing to the increase in healthcare expenditure, rising awareness about early diagnosis, high unmet clinical needs of patients, and availability of effective treatment in emerging countries, such as China and India.

Competitive Landscape

The Blood Cancer Drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly. Bristol-Myers Squibb Company, Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, UCB SA among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the blood cancer drugs market globally.

Amgen Inc

Overview: Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis, Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.

Product Portfolio: The Company's portfolio comprised of inflammation, oncology/hematology, bone health, cardiovascular disease, and nephrology and neuroscience areas.

Key Development: In January 2016, Amgen and Merck announced a cancer immunotherapy collaboration to support a Phase 1b/3 study investigating BLINCYTO (blinatumomab) in combination with KEYTRUDA (pembrolizumab) in patients with diffuse large B-cell lymphoma (DLBCL), which is the most common type of non-Hodgkin lymphoma (NHL). BLINCYTO is Amgen's CD19 bispecific T cell engager (BiTE), and KEYTRUDA is Merck's anti-PD-1 therapy. The study is an open-label, multicenter, randomized trial to evaluate safety and efficacy in patients with DLBCL.

Why Purchase the Report?

  • Visualize the composition of the blood cancer drugs market segmentation by type, drugs type, Route of Administration, and end user highlighting the key commercial assets and players.
  • Identify commercial opportunities in blood cancer drugs market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of blood cancer drugs market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global blood cancer drugs market report would provide an access to an approx. 70 market data table, 68 figures and 200 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Blood Cancer Drugs Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Blood Cancer Drugs Market - Market Definition and Overview

3. Global Blood Cancer Drugs Market - Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market snippet by Drug Type
  • 3.3. Market snippet by Route of Administration
  • 3.4. Market Snippet by End User
  • 3.5. Market Snippet by Region

4. Global Blood Cancer Drugs Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1.
      • 4.1.1.2. The growing death incidences and increasing prevalence of blood cancer cases across the globe
      • 4.1.1.3. Formulations of new regulatory approvals for new drugs for blood cancer are expected to drive the growth
    • 4.1.2. Restraints:
    • 4.1.3. High drug approval costs hinders the growth of the blood cancer drugs market
    • 4.1.4. Opportunity
    • 4.1.5. Impact Analysis

5. Global Blood Cancer Drugs Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Blood Cancer Drugs Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Blood Cancer Drugs Market - By Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
  • 7.3. Market Attractiveness Index, By Type Segment
    • 7.3.1. Leukemia*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
      • 7.3.1.3. Nucleoside Reverse transcriptase inhibitors (NRTIs)
    • 7.3.2. Non-Hodgkin lymphoma
    • 7.3.3. Hodgkin lymphoma
    • 7.3.4. Myeloma

8. Global Blood Cancer Drugs Market - By Drugs Type

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drugs Type
  • 8.3. Market Attractiveness Index, By Drugs Type
    • 8.3.1. Rituaxan/Mabthera (Rituximab)*
      • 8.3.1.1.1. Introduction
      • 8.3.1.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Gleevac/Glivec (Imatinib)
    • 8.3.3. Revlimid (Lenalidomide)
    • 8.3.4. Velcade (Bortezomib)
    • 8.3.5. Tasigna (Nilotinib)
    • 8.3.6. Pomalyst (Pomalidomide)
    • 8.3.7. Vidaza (Azacitidine)
    • 8.3.8. Kyprolis (Carfilzomib)
    • 8.3.9. Adcetris (Brentuximab Vedotin)
    • 8.3.10. Others

9. Global Blood Cancer Drugs Market - By Route of Administration

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.3. Market Attractiveness Index, By Route of Administration
    • 9.3.1. Oral *
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Parenteral
    • 9.3.3. Others

10. Global Blood Cancer Drugs Market - By End User

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
  • 10.3. Market Attractiveness Index, By End User Segment
    • 10.3.1. Hospitals *
      • 10.3.1.1. Introduction
      • 10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 10.3.2. Clinics
    • 10.3.3. Ambulatory Surgical Centers

11. Global Blood Cancer Drugs Market - By Region

  • 11.1. Introduction
  • 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 11.3. Market Attractiveness Index, By Region
  • 11.4. North America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drugs Type
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. U.S.
      • 11.4.7.2. Canada
      • 11.4.7.3. Mexico
  • 11.5. Europe
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drugs Type
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Distribution Channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. Germany
      • 11.5.7.2. U.K.
      • 11.5.7.3. France
      • 11.5.7.4. Italy
      • 11.5.7.5. Spain
      • 11.5.7.6. Rest of Europe
  • 11.6. South America
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drugs Type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.6.7.1. Brazil
      • 11.6.7.2. Argentina
      • 11.6.7.3. Rest of South America
  • 11.7. Asia Pacific
    • 11.7.1. Introduction
    • 11.7.2. Key Region-Specific Dynamics
    • 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drugs Type
    • 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.7.7.1. China
      • 11.7.7.2. India
      • 11.7.7.3. Japan
      • 11.7.7.4. Australia
      • 11.7.7.5. Rest of Asia Pacific
  • 11.8. Middle East and Africa
    • 11.8.1. Introduction
    • 11.8.2. Key Region-Specific Dynamics
    • 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drugs Type
    • 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Global Blood Cancer Drugs Market - Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Global Blood Cancer Drugs Market- Company Profiles

  • 13.1. Amgen Inc. *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. AstraZeneca PLC
  • 13.3. Bayer AG
  • 13.4. Celgene Corporation
  • 13.5. Eli Lilly
  • 13.6. Bristol-Myers Squibb Company
  • 13.7. Gilead Sciences, Inc.
  • 13.8. Takeda Pharmaceutical Company Limited
  • 13.9. Daiichi Sankyo Company, Limited
  • 13.10. UCB SA

LIST NOT EXHAUSTIVE

14. Global Blood Cancer Drugs Market - Premium Insights

15. Global Blood Cancer Drugs Market - DataM

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us